com Where applicable, payment of this compensation would be in full and final settlement of all claims other than in respect of share options or awards and pension arrangements.
In an appropriate case the Directors would have regard to the departing Directors duty to mitigate loss, except in the event of dismissal following a change of control of the Company.
Other than as described above, there are no express provisions within the Directors service contracts for the payment of compensation or liquidated damages on termination of employment.
No compensation payments were made to Executive or Non-Executive Directors during the year.
Non-Executive Directors The Board aims to recruit and retain Non-Executive Directors of a high calibre with the requisite experience required to achieve success for the Company and its Shareholders.
The fees of the Chairman are determined by the Committee and the fees of the Non-Executive Directors are determined by the Board following a recommendation from both the Chief Executive and the Chairman.
It should be noted that neither the Chairman nor the NonExecutive Directors take part in the determination of their own remuneration.
Non-Executive Directors are paid a basic fee with additional fees paid for the chairing of Committees.
Taking into account the current economic climate and the pay increases across the Group, the Non-Executive Directors have waived an increase in their fees for the 2009 2010 financial year.
The annual fee level for 2009 10 therefore remains at the level paid for 2008 2009: Fee Office 000 Chairman 80 Non-Executive Director 31 Senior Non-Executive additional fee 3 Remuneration Committee Chairmanship additional fee 5 Audit Committee Chairmanship additional fee 8 Non-Executive Directors are not eligible to participate in any of the Companys share schemes, incentive schemes or pension schemes.
Directors Shareholdings The beneficial interests of the Directors in office and their families in the share capital of Dechra Pharmaceuticals PLC as at 30 June 2009 were as follows: Ordinary Ordinary Shares Shares Shareholdings 2009 2008 Michael Redmond 56,475 41,475 Ian Page 679,856 759,332 Simon Evans 830,274 806,370 Ed Torr 390,783 426,796 Malcolm Diamond 10,007 6,100 Neil Warner 2,691 2,691 There have been no changes in the holdings of the Directors between 30 June and 1 September 2009.
55 16782 08 09 2009 Proof 9 Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2009 Directors Remuneration Report continued Total Shareholder Return The graphs below shows the Total Shareholder Return performance of the Company over the past five financial years compared with the Total Shareholder Return over the same period for the FTSE Small Cap Total Return Index and FTSE 250 Index.
During the 2008 2009 financial year the Company moved from the FTSE Small Cap Index to become a constituent member of the FTSE 250: for this reason it is considered that the Total Shareholder Return performance of both sectors be represented in this report.
400 400 DECHRA TSR DECHRA TSR 350 350 FTSE 250 TSR FTSE SMALL CAP TSR 300 300 250 250 200 200 150 150 100 100 50 50 0 0 Effectiveness Review During the year, the Committee reviewed its effectiveness through a process led by the Committee Chairman.
The Committee considered it had the skills and experience necessary to perform its responsibilities.
These findings were reported to the Committee and the Board.
Audited Information The auditors are required to report on the information contained in the remainder of this report.
Summary of Remuneration Salaries Other Total Total & Fees Bonuses Benefits 2009 2008 000 000 000 000 000 Executive Directors Ian Page Chief Executive 350 287 28 665 549 Simon Evans 220 181 24 425 327 Ed Torr 210 172 15 397 293 Non-Executive Directors Michael Redmond Chairman 80 80 60 Malcolm Diamond 39 39 31 Neil Warner 39 39 29 938 640 67 1,645 1,289 Executive bonuses for the year ended 30 June 2009 as reflected in the table above were determined as follows: l Profit performance 10% of salary payable upon the achievement of 95% of Group profit target rising to 90% of salary payable upon the achievement of 110% of Group profit target.
Actual performance reflected 107% of the profit target resulting in a payment worth 74% of salary.
l Personal objectives up to an additional 10% of salary was payable to Executive Directors upon the achievement of personal objectives.
Actual performance resulted in payments worth 8% of salary.
No awards vest unless the Committee is satisfied with the underlying financial performance of the Company over the performance period.
Following the approval of the Long Term Incentive Plan at the 2008 Annual General Meeting no options have been granted under the EIP during the financial year under review.
During the financial year awards granted in 2005 became exercisable.
Independent verification by Hewitt New Bridge Street showed that the Companys TSR performance for the three year period to 30 June 2008 was in the top quartile of the FTSE Small Cap Total Return Index.
The Committee also determined that the underlying financial performance of the Company over the performance period had been satisfactory.
The full award was therefore exercisable.
Independent verification has also recently been sought from Hewitt New Bridge Street in respect of the satisfaction of the performance targets for awards which vested as at 30 June 2009.
It has been confirmed to the Committee that the Companys TSR performance for the three year period to 30 June 2009 was again in the top quartile of the FTSE Small Cap Total Return Index.
Subject to the Committee confirming that the underlying financial performance of the Company has been satisfactory throughout the performance period, the awards will be capable of exercise for a 90 day period commencing on 1 September 2009.
57 16782 08 09 2009 Proof 9 Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2009 Directors Remuneration Report continued Long Term Incentive Plan The Long Term Incentive Plan was approved by Shareholders at the 2008 Annual General Meeting.
The following awards were made on 19 November 2008: Number of Granted Exercised shares at Share price Award during during 30 June Performance at date date the year the year 2009 period of award Ian Page 2009 92,593 92,593 20082011 391.75 Simon Evans 2009 58,201 58,201 20082011 391.75 Ed Torr 2009 55,556 55,556 20082011 391.75 The performance conditions attaching to the Long Term Incentive Plan are explained on page 53.
The aggregate gain made by the Executive Directors on share options exercised during 2009 was 330,979.
The aggregate gain made by the Executive Directors on share options exercised during 2008 was 589,000.
SAYE Scheme Directors entitlements under the SAYE Scheme are as follows: Market price At At at date Exercise 30 June 30 June Award of grant price Exercise 2008 Exercised Granted Lapsed 2009 date pence pence dates number number number number number Ian Page 13 October 2008 387 343 Dec 2013 4,883 4,883 Simon Evans 13 October 2008 387 343 Dec 2013 4,883 4,883 Ed Torr 18 October 2005 255 204 Dec 2008 2,750 2,750 13 October 2008 387 343 Dec 2011 1,119 1,119 2,750 2,750 10,885 10,885 Share Price The middle market price for the Companys shares on 30 June 2009 was 422.25p and the range of prices during the year was 315.5p to 442.75p.
Pension Entitlement All Executive Directors were members of the Dechra Pharmaceuticals PLC Group Stakeholder personal pension scheme throughout the year.
Contributions made by Dechra Pharmaceuticals PLC on behalf of the Executive Directors during the year are based on a percentage of pensionable salary and were paid as follows: Contributions Contributions 2009 2008 Age 000 000 Ian Page 48 49 42 Simon Evans 45 31 25 Ed Torr 49 29 22 109 89 By order of the Board Malcolm Diamond Chairman Remuneration Committee 1 September 2009 58 16782 08 09 2009 Proof 9
